Page 221 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Classification and Pathogenicity of ANCA-Associated Vasculitis 197

[130] Ohta, N. Th1 and Th2 CD4+ T-cells and Tc1 and Tc2 CD8+ T-cells of patients with
Wegener's Granulomatosis. J. Laryngol. Otol. 2002; 116:605-609.

[131] Balding, C. E. J. Th2 dominance in nasal mucosa in patients with Wegener's
Granulomatosis. Clin. Exp. Immunol. 2001; 125:332-339.

[132] Yoshimura, J., Fukami, K., Koike, K., et al. Interstitial Foxp3-positive T cells may
predict renal survival in patients with myeroperoxidase anti-neutrophil cytoplasmic
antibody-associated glomerulonephritis. Clin. Exp. Pharmacol. Physiol. 2010; 37:879-
883.

[133] Abdulahad, W. H., van der Geld, Y. M., Stegeman, C. A., et al. Persistent expansion of
CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 2006; 70:938-
947.

[134] Schmitt, W., Hagen, E., Neumann, I., et al., and the European Vasculitis Study Group.
Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG):
an open study in 15 patients. Kidney Int. 2004; 65:1440-1448.

[135] Giscombe, R., Nityanand, S., Lewin, N., et al. Expanded T cell populations in patients
with Wegener's granulomatosis: characteristics and correlates with disease activity. J.
Clin. Immunol. 1998; 18:404-413.

[136] Popa, E. R., Stegeman, C. A., Bos, N. A., et al. Differential B- and T-cell activation in
Wegener's granulomatosis. J. Allergy Clin. Immunol. 1999; 103:885-894.

[137] Schlesier, M., Kaspar, T., Gutfleisch, J., et al. Activated CD4+ and CD8+ T-cell subsets
in Wegener's granulomatosis. Rheumatol. Int. 1995; 14:213-219.

[138] Lamprecht, P., Bruhl, H., Erdmann, A., et al. Differences in CCR5 expression on
peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized
and generalized Wegener's granulomatosis. Clin. Immunol. 2003; 108:1-7.

[139] Moosig, F., Csernok, E., Wang, G., et al. Costimulatory molecules in Wegener's
granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its
ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin. Exp. Immunol. 1998; 114:113-
118.

[140] Komocsi, A., Lamprecht, P., Csernok, E., et al. Peripheral blood and granuloma
CD4+CD28- T-cells are a major source of interferon gamma and tumour necrosis factor
alpha in Wegener's Granulomatosis. Am. J. Pathol. 2002; 160:1717-1724.

[141] Morgan, M. D., Pachnio, A., Begum, J., et al. CD4+CD28- T-cell expansion in
Wegener's granulomatosis is driven by latent CMV and is associated with an increased
risk of infection and mortality. Arthritis Rheum. 2011; 63:2127-2137.

[142] Voswinkel, J., Mueller, A., Kraemer, J. A., et al. B lymphocyte maturation in
Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions.
Ann. Rheum. Dis. 2006; 65:859-864.

[143] Eriksson, P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis
successfully treated with rituximab. J. Intern. Med. 2005; 257:540-548.

[144] Ferraro, A. J., Day, C. J., Drayson, M. T., and Savage, C. O. Effective therapeutic use
of rituximab in refractory Wegener's granulomatosis. Nephrol. Dial. Transplant. 2005;
20: 622-625.

[145] Culton, D. A., Nicholas, M. W., Bunch, D. O., et al. Similar CD19 dysregulation in two
autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell
tolerance loss. J. Clin. Immunol. 2007; 27:53-68.

Complimentary Contributor Copy